

16 February 2022

Usage of Intra-Vitreous Injections or Implants in Belfast Health and Social Care Trust

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions:

1. For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreous injections or implants) for each of the following eye conditions:

- Wet Age-Related Macular Degeneration (wAMD) 3273
- Diabetic Macular Oedema (DMO) 881
- Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO) 746
- Any other eye condition 342

2. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2021:

- Aflibercept 3480
- Bevacizumab 6
- Brolucizumab 0
- Dexamethasone 34
- Fluocinolone acetonide 3
- Ranibizumab 1719

3. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2021.

Number of Injections/Implants: Sep to Dec 2021

Treatment	Eye Conditions		
	wAMD	DMO	RVO
Aflibercept	2304	475	107
Bevacizumab	2	1	0
Brolucizumab	0	0	0
Dexamethasone	0	1	4
Fluocinolone acetonide	0	0	0
Ranibizumab	954	404	29